Larry Ellison
Co-Founder @ Tako Ventures
Redwood Shores, United States
Larry Ellison is a Series C investor at Tako Ventures in Redwood Shores focused on Software and Health Care. Larry Ellison is the Co-Founder, Executive Chairman, and CTO of Oracle. He attended the University of Chicago.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Larry Ellison invests in
Stages Larry Ellison invests in
Countries Larry Ellison invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 3 (20%)
- Health Care 3 (20%)
- Biotechnology 3 (20%)
- SaaS 2 (13%)
- Health Diagnostics 2 (13%)
Stage
- Series C 3 (20%)
- Series B 2 (13%)
- Series G 2 (13%)
- Series H 2 (13%)
- Funding Round 2 (13%)
Country
- United States 7 (47%)
- Spain 1 (7%)
- Israel 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Imagene AI provides AI-based molecular testing for cancer, leveraging the patient's histological data for personalized therapy.Our mission at Imagene is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from thebiopsy image alone. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is revolutionizing molecular screening for both clinical practice and research.Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts. | $23M / Series B / Jul 01, 2025 | ||
| Imagene AI provides AI-based molecular testing for cancer, leveraging the patient's histological data for personalized therapy.Our mission at Imagene is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from thebiopsy image alone. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is revolutionizing molecular screening for both clinical practice and research.Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts. | $18.5M / Series A / May 02, 2022 | ||
| Kosmos Tennis is pleased to announce the launch of www.daviscupfinals.com, which will be operational as of 22nd January, to keep the public informed about all aspects of the new Davis Cup Finals. The new website provides easy and intuitive access to all aspects of the new competition format, especially the finals, which will bring 18 national teamstogether in the same city over the course of a week. The new website will also report on the most significant events of the qualifiers set to take place in February. | $65.8M / Venture - Series Unknown / Oct 02, 2019 | ||
| Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR†technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for theoccurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified. | $13.9M / Series H / Apr 18, 2008 | ||
| Theranos was a privately-held consumer healthcare technology company that is now arguably the largest biomedical fraud in U.S. history. Its founder, Elizabeth Holmes, was convicted of investor fraud after a series of Wall Street Journal (WSJ) articles that revealed the tests the company claimed to be doing were actually being carried out bytraditional machines purchased from other companies. At its peak, it was valued at $10 billion. | $28.5M / Series C / Nov 17, 2006 | ||
| NetSuite is cloud computing company dedicated to delivering business applications over the internet. It provides a suite of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries.The company was founded 1998 and is based in San Mateo,California. | $20M / Debt Financing / Mar 01, 2006 | ||
| Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR†technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for theoccurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified. | $10.5M / Series G / Jan 01, 2006 | ||
| NetSuite is cloud computing company dedicated to delivering business applications over the internet. It provides a suite of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries.The company was founded 1998 and is based in San Mateo,California. | $15M / Series H / Apr 01, 2005 | ||
| A4Vision (Applications for Vision) develops and licenses Advanced identification systems and tracking solutions using 3D facial imaging and recognition technology.A4Vision products are designed for broad security applications such as surveillance and access control, law enforcement and commercial markets such as PC and Internet applications.A4Vision’s 3D facial and camera systems are based on a combination of patented optical technology, targeting and tracking software, and recognition algorithms. Through innovations in the 3D data capturing and processing capabilities, these systems permit industry-leading accuracy in real-time facial recognition and tracking. | $4.8M / Series B / Oct 27, 2004 | ||
| NetSuite is cloud computing company dedicated to delivering business applications over the internet. It provides a suite of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries.The company was founded 1998 and is based in San Mateo,California. | $19.9M / Series G / Jan 01, 2004 | ||
| See all 15 investments → | |||
Co-Investors
About Tako Ventures
Tako Ventures is a venture capital firm that caters to biotechnology companies. The company was founded by Larry Ellison and is based in San Francisco, California.
Tako Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Larry Ellison
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Larry Ellison invest in?
Larry Ellison invests primarily in Software, Health Care and Biotechnology startups, most often at Series C and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Larry Ellison?
Public channels for Larry Ellison include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Larry Ellison last invest?
The most recent investment recorded for Larry Ellison closed in Jul 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
